Trial reportEuropean journal of nutrition2026
Curcuma longa improves endothelial glycocalyx integrity and redox-inflammatory pathways in type 2 diabetes mellitus: a randomized double-blind placebo-controlled study.
Trial report in European journal of nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond the Rhizome: Phytochemistry, Biological Activities, and Sustainable Utilization ofPharmaceuticals (Basel, Switzerland) · 2026Review
- From Plant Chemistry to Reproducible Antidiabetic Products: A Critical Review of Molecular Targets, Clinical Evidence, and Translational Gaps.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis randomized, double-blind, placebo-controlled trial investigated the effects of Curcuma longa extract (CLE) supplementation on vascular, redox-inflammatory biomarkers, and neuropathy symptoms in adults with type 2 diabetes mellitus (T2DM).
methodsSeventy-six adults with T2DM were randomized to receive CLE (1200 mg/day) or placebo for three months. Plasma concentrations of hyaluronic acid (HA), syndecan-1 (SDC1), syndecan-4 (SDC4), matrix metalloproteinases (MMP-2 and MMP-9), thioredoxin-1 (Trx1), thioredoxin-binding protein-2 (TBP2), sirtuin-1 (SIRT1), nuclear factor erythroid 2–related factor 2 (Nrf2), and the p65 subunit of nuclear factor kappa B (NF-κB p65) were measured at baseline and post-intervention. Neuropathy symptoms were assessed using a validated questionnaire.
resultsBaseline characteristics were comparable between groups. After 3 months, CLE supplementation resulted in a significant reduction in neuropathy symptom score compared with placebo (P = 0.048). CLE significantly reduced markers of endothelial glycocalyx shedding, including SDC1 (66.5 vs. 113.0 ng/mL; P = 0.001), SDC4 (155.1 vs. 225.5 pg/mL; P = 0.040), and HA (259.8 vs. 371.7 ng/mL; P = 0.002), as well as MMP-2 (198.4 vs. 233.3 ng/mL; P < 0.001) and MMP-9 (1.2 vs. 2.0 ng/mL; P < 0.001). In parallel, CLE increased antioxidant/redox markers Trx1, SIRT1, and Nrf2 (all P < 0.05) and reduced TBP2 and NF-κB p65 levels (both P < 0.001), indicating coordinated modulation of vascular, redox, and inflammatory pathways.
conclusionShort-term supplementation with CLE was associated with favorable modulation of vascular and redox-inflammatory biomarkers and improvement in neuropathy symptoms in adults with T2DM. These findings support the role of CLE as a promising bioactive nutritional supplement for the prevention and management of vascular and neuropathic complications associated with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.